阿仑膦酸钠预防来曲唑引起的绝经后早期乳腺癌患者骨量丢失的疗效  

Prevention Effect of Alendronate Sodium on Letrozole-Associated Bone Loss in the Postmenopausal Women with Early Breast Cancer

作　　者：胡慧[1] 周正仕[1] 廖小方[1] 

机构地区：[1]衢州市人民医院放疗科,浙江衢州324000

出　　处：《肿瘤基础与临床》2012年第2期151-153,共3页journal of basic and clinical oncology

摘　　要：目的探讨阿仑膦酸钠预防来曲唑引起的绝经后早期乳腺癌患者骨量丢失的疗效。方法选择服用来曲唑的绝经后乳腺癌患者82例,随机分为2组。A组42例服用来曲唑,B组40例服用来曲唑的同时给予阿仑膦酸钠治疗。分别在服用来曲唑前及服药后6、12个月采用双能X线骨密度仪对82例绝经后乳腺癌患者进行骨密度(BMD)检测。结果 2组患者接受来曲唑治疗后6、12个月,BMD均出现下降;来曲唑治疗后12个月,A组较B组BMD下降更明显(P均<0.05)。结论来曲唑可加剧绝经后乳腺癌患者骨量丢失;应用阿仑膦酸钠可有效减轻患者的骨量丢失。Objective To analyze the prevention effect of alendronate sodium on letrozole-associated bone loss in postmenopausal women with early breast cancer. Methods The 82 postmenopausal women with early breast cancer were enrolled randomly into two groups. The 42 women in the A group were administered by letrozole,the 40 women in the B group were administered by letrozole and alendronate sodium. Bone mineral density （BMD） was detected by dual X-ray absorptiometry before treatment and in 6,12 months after treatment. Results In the two groups,the BMD had the decrease in 6 and 12 months after treatment. BMD change in the A group was larger than that in the B group in 12 months after treatment （ P 〈 O. 05 ）. Conclusion Letrozole can promote bone loss in the postmenopaus- al women with early breast cancer; alendronate sodium could prevent the bone loss.

关 键 词：来曲唑 骨量丢失 乳腺肿瘤 阿仑膦酸钠 

分 类 号：R737.9[医药卫生—肿瘤] R730.6[医药卫生—临床医学]